Last updated: February 25, 2026
What is NDC 64380-0707?
The National Drug Code (NDC) 64380-0707 corresponds to Veklury (remdesivir), an antiviral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19.
Market Context and Demand
Current Usage and Demand
- The use of remdesivir surged during the COVID-19 pandemic, with widespread hospital adoption.
- As of 2022, prescriptions decline in regions with increasing vaccination rates and new treatment options.
- During 2020-2022, demand was driven by COVID-19 hospitalization rates, with peaks correlating to infection surges.
Competitive Landscape
- Other approved COVID-19 treatments include molnupiravir, paxlovid, and monuleclast.
- Remdesivir's market share faced erosion from oral antivirals that offer ease of administration.
- Hospital protocols' retention of IV remdesivir remains critical for severe COVID-19 cases.
Market Segmentation
| Segment |
Key Characteristics |
Market Size (USD Millions) |
| Hospitals |
Primary use, FDA-approved for severe cases |
450 (2022 estimate) |
| Outpatient clinics |
Limited use, mostly in clinical trials |
50 |
| International markets |
Growing use in Europe, Asia |
300 |
Regulatory Factors
- FDA approval in October 2020.
- Emergency Use Authorization (EUA) expanded in late 2020.
- Ongoing clinical trials extend potential indications, possibly affecting future demand.
Price Dynamics and Projections
Historical Pricing
- Wholesale acquisition cost (WAC) for a 100 mg vial was approximately $520 in 2020.
- The average treatment course involves six vials, totaling around $3,120 per patient.
- Post-pandemic, prices have stabilised with minor fluctuations.
Current Pricing Environment
| Price Element |
Details |
| Wholesale Price (WAC) |
~$520 per 100 mg vial (2022) |
| Market Price |
Approx. $520–$550 per vial, depending on negotiations |
| Cost per Treatment |
~$3,120 (assuming 6 vials) |
Price Influencers
- Negotiations with insurers and government agencies influence actual purchase prices.
- Volume discounts are common for bulk hospital and government contracts.
- Patent exclusivity expiration impacts generic entry and price competition.
Price Forecasts (2023–2027)
| Year |
Estimated Price Range |
Key Factors |
| 2023 |
$500–$600 per vial |
Contract negotiations, stabilization post-pandemic |
| 2024 |
$480–$550 per vial |
Increased generic competition, potential price erosion |
| 2025 |
$450–$500 per vial |
Greater generics market penetration, price pressure |
| 2026 |
$430–$480 per vial |
Market saturation, regulatory changes |
| 2027 |
$400–$450 per vial |
Generic dominance, alternative treatments gaining traction |
Market Drivers for Price Changes
- Patent expiration in late 2023 or early 2024 would introduce generics.
- New indications or fusion of combination therapies could bolster demand.
- Changes in COVID-19 management strategies influence hospital spending.
Geographical Pricing Variations
| Region |
Price Range (USD per vial) |
Status |
| U.S. |
$520–$550 |
Market leader |
| Europe |
Similar to U.S., slight discounts |
Widely used in major countries |
| Asia |
$400–$500 |
Discounted, driven by local negotiations |
Strategic Implications
- Launch of generics expected to end current price stability.
- Manufacturers should prepare for increased competition in 2024-2025.
- R&D investments in new antiviral derivatives under consideration to extend market presence.
Key Takeaways
- NDC 64380-0707 (remdesivir) experienced peak demand during the COVID-19 pandemic.
- Current wholesale prices remain around $520 per vial, with future decline anticipated due to patent expiry and generics.
- Market projections indicate prices will decline steadily over the next four years, stabilizing around $400–$450 per vial.
- Hospital contracts and government negotiations are primary price influencers.
- Geographic price differences exist but are relatively modest, with the U.S. and Europe maintaining the highest prices.
FAQs
What factors impact remdesivir pricing most significantly?
Negotiations with payers, patent statuses, and the entry of generics influence prices the most.
When is generic remdesivir expected to enter the market?
Pending patent expiration, expected in late 2023 or early 2024.
How will new COVID-19 treatments affect remdesivir's market?
Oral antivirals and combination therapies could reduce remdesivir's hospital-based demand and market share.
Are there ongoing clinical trials that might extend remdesivir’s indications?
Yes, multiple trials explore additional viral illnesses and newer COVID-19 variants.
How do international markets affect global pricing?
Pricing varies based on local healthcare policies, negotiation power, and market size, generally lower outside the U.S.
References
- U.S. Food and Drug Administration. (2020). FDA approves first treatment for COVID-19. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
- IQVIA Institute. (2022). The Global Use of Medicines in 2022. IQVIA.
- MarketWatch. (2022). Remdesivir prices and market overview. https://www.marketwatch.com/
- European Medicines Agency. (2023). Regulatory status of remdesivir in Europe. https://www.ema.europa.eu/en
- Statista. (2023). COVID-19 antiviral drug sales worldwide. https://www.statista.com/
